Acute Heart Failure (AHF) Registry Würzburg
| ISRCTN | ISRCTN65006275 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN65006275 |
| Protocol serial number | N/A |
| Sponsor | University of Würzburg (Universitätsklinikum Würzburg) (Germany) |
| Funder | German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung [BMBF]) (Germany) |
- Submission date
- 04/08/2014
- Registration date
- 16/10/2014
- Last edited
- 16/09/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Documented information about the outcome of treatments for patients with acute heart failure (AHF) during their stay in hospital and during their follow-up visits is very scarce. Further, no up-to-date data are available on in-patient clinical profiles in the critical stages. Follow-up data are lacking, including documentation of heart function that can help in the understanding of the type and severity of heart failure, modern treatment patterns after a hospitalization for AHF, management of risk factors and associated diseases (e.g. kidney failure or anaemia) and information on type and rates of complications. It is also unknown how many patients after a hospital admission for acute heart failure will, in the long run, develop advanced heart failure. The AHF registry is an initiative of the Comprehensive Heart Failure Center Wuerzburg. It is a forthcoming short- and long-term registry of HF patients, enrolled at the time of hospitalization for AHF, which will help to address the above listed knowledge gaps. The AHF registry will be capable of identifying unmet medical, psychosocial and palliative needs, monitor the impact of new drug-related as well as surgical treatment options for HF, and direct future HF research.
Who can participate?
Adult patients who are hospitalized for acute heart failure.
What does the study involve?
The study involves a complete data collection during the hospital stay and regular follow-up visits up to 5 years to assess the patients' health status. This registry is necessary to document the natural history of AHF, and associated long-term HF treatment patterns including re-hospitalization rates, specific treatment patterns for certain risk factors and other diseases that can be associated with HF, clinical outcomes, quality of life (QoL), brain function, depression and standardized evaluation of palliative requirements. This 'real world' data collection study will not interfere with the usual care of patients, and will not lead to specific diagnostic procedures or treatments. Study data will be collected during routine visits.
What are the possible benefits and risks of participating?
Patients might benefit from regular examinations; however, there is no immediate benefit. The results of the data collection in the registry might in future contribute to a better diagnosis and treatment of acute heart failure. There are no risks to participating.
Where is the study run from?
University Hospital in Wuerzburg, Germany.
When is the study starting and how long is it expected to run for?
August 2014 until August 2025.
Who is funding the study?
The Federal Ministry of Education and Research (Germany).
Who is the main contact?
Prof. Dr med. C. Angermann
angermann_c@ukw.de
Contact information
Scientific
Straubmühlweg 2a
Wuerzburg
97078
Germany
| angermann_c@ukw.de |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Prospective cohort study |
| Secondary study design | Cohort study |
| Study type | Participant information sheet |
| Scientific title | Prospective cohort study on etiology, clinical Features, costs, palliative needs and outcomes in acute heart failure |
| Study acronym | AHF Registry Würzburg |
| Study objectives | 1. Analyses of the data will significantly improve the pathophysiological knowledge about AHF and in particular about the early phase after cardiac decompensation, worsening, progressive and advanced HF. Further, it will provide by prospective assessment of treatment efficacy a rational basis for future differential treatment allocation in patients with AHF and advanced HF considering also HF etiology and course. 2. Since consecutive patients will be recruited on a 7 day/24 hour basis, a representative profile of the various etiologies and clinical representations of AHF will for the first time be generated in the frame of the German healthcare system. 3. Data generated from this study can be used to better define significant prognostic characteristics and guide short-term management and maintenance treatment decisions. 4. With this study it will be possible to identify so far unmet needs of the participants. 5. Data generated from the study will allow monitoring the impact of novel pharmacological and surgical HF treatment options on the clinical short- and long-term course and direct future HF research. 6. Systematic longitudinal characterization of the clinical profile of advanced HF patients including documentation of outcome data in relation to applied treatment modalities will generate reliable information on the natural course of the disease as well as on the short- and long-term effects of specific pharmacological, interventional and surgical procedures in these 'real life' patients beyond the data available from randomized clinical trials. |
| Ethics approval(s) | Ethics Committee of the University of Wuerzburg, July 2014, ref. 55/14 |
| Health condition(s) or problem(s) studied | Acute heart failure |
| Intervention | There is no intervention in this study. The data collection for the AHF Registry Würzburg does not interfere with any routine diagnostic or therapeutic procedures. There are no additional study-related examinations or procedures. |
| Intervention type | Other |
| Primary outcome measure(s) |
Incidence of post-discharge events (re-hospitalization and cause-specific death) during the observation period |
| Key secondary outcome measure(s) |
1. Proportion of patients with HFrEF versus HFpEF at the time of the index hospitalization |
| Completion date | 31/08/2025 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 1000 |
| Key inclusion criteria | 1. Age >18 years 2. Hospitalization with AHF (de novo/decompensated chronic HF) according to the clinical judgment of the responsible physician 3. Written informed consent |
| Key exclusion criteria | 1. Cardiogenic shock 2. High output heart failure 3. On waiting list for urgent HTX |
| Date of first enrolment | 01/08/2014 |
| Date of final enrolment | 31/08/2020 |
Locations
Countries of recruitment
- Germany
Study participating centre
97078
Germany
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
16/09/2021: The overall trial end date has been changed from 31/08/2020 to 31/08/2025 and the plain English summary has been updated accordingly.
